<DOC>
	<DOCNO>NCT02925546</DOCNO>
	<brief_summary>GSK2798745 develop novel therapeutic intervention treatment pulmonary edema associate heart failure ( HF ) currently investigation form compound capsule . This open-label , randomize , single-dose , crossover study purpose determine pharmacokinetics ( PK ) three 2.4 milligram ( mg ) tablet formulation GSK2798745 12 healthy subject . The three formulation develop study micronized GSK2798745 active pharmaceutical ingredient ( API ) ( Tablet A ) , micronized GSK2798745 API sodium lauryl sulfate ( SLS ) hypromellose ( Tablet B ) , mill GSK2798745 API SLS hypermellose ( Tablet C ) , Tablet D , either A/B/C base interim PK analysis data first three treatment period . Following 30-day screening period , subject randomize one 6 treatment sequence : Treatment sequence 1 : ABCD , 2=CABD , 3=ACBD , 4=BACD , 5=BCAD , 6=CBAD three 4-day treatment period . For treatment period 4 , best formulation base interim analysis data three treatment period evaluate fed condition . Each treatment period separate minimum 7 ( +14 ) -day washout period . The total duration participation study approximately 11 week include follow-up visit .</brief_summary>
	<brief_title>A Phase I Study Assess Pharmacokinetics GSK2798745 Tablets</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Between 18 75 year age inclusive , time signing informed consent Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor require agree document find unlikely introduce additional risk factor interfere study procedure Body weight &gt; =50 kg body mass index within range 18 32 kilogram ( kg ) /meter ( ) ^2 ( inclusive ) Male female nonchild bear potential : A male subject female partner child bear potential eligible participate agrees use contraception mention protocol treatment period least 7 day last dose study treatment refrain donate sperm period A female subject eligible participate woman childbearing potential ( WOCBP ) define protocol . Capable give sign informed consent include compliance requirement restriction list consent form protocol History acute coronary syndrome include unstable angina myocardial infarction within 6 month screen History stroke seizure disorder within 5 year Screening Active ulcer disease gastrointestinal bleeding time screen Alanine transaminase ( ALT ) bilirubin &gt; 1.5x Upper limit normal ( ULN ) acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) QT interval correct accord Fridericia 's formula ( QTcF ) &gt; 450 millisecond ( msec ) History current evidence serious clinically significant gastrointestinal , renal , endocrine , neurologic , hematologic condition uncontrolled permitted therapy would , opinion investigator Medical Monitor , make subject unsuitable inclusion study Urinary cotinine level indicative current smoking regular use tobacco nicotinecontaining product time screening ( cotinine level &gt; 200 nanogram [ ng ] /millimeter [ mL ] ) History alcohol abuse within 6 month study base follow criterion : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation Presence hepatitis B surface antigen , positive hepatitis C antibody test result screen within 3 month screen . A positive test human immunodeficiency virus antibody A positive prestudy drug/alcohol screen A screening cardiac Troponin level &gt; ULN Use another investigational product clinical study within follow time period prior first administration study medication current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) Exposure 4 investigational medicinal product within 12 month prior first administration study medication . Unable refrain use prescription nonprescription drug ( include vitamin dietary herbal supplement ) except permit medication list protocol , within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication completion followup visit , unless opinion Investigator and/ sponsor medication interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
	<keyword>GSK2798745</keyword>
	<keyword>Tablet</keyword>
</DOC>